# A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

> **NCT06045806** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 79 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** idecabtagene vicleucel
- **DRUG:** Lenalidomide
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06045806
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-16
- **Primary completion:** 2025-08-11
- **Final completion:** 2029-11-20
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045806, "A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06045806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*